CN101111235A - 含有pde4调节剂的组合物以及它们在治疗或预防气道炎症中的用途 - Google Patents

含有pde4调节剂的组合物以及它们在治疗或预防气道炎症中的用途 Download PDF

Info

Publication number
CN101111235A
CN101111235A CNA2005800476591A CN200580047659A CN101111235A CN 101111235 A CN101111235 A CN 101111235A CN A2005800476591 A CNA2005800476591 A CN A2005800476591A CN 200580047659 A CN200580047659 A CN 200580047659A CN 101111235 A CN101111235 A CN 101111235A
Authority
CN
China
Prior art keywords
carbon atoms
alkyl
substituted
group
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800476591A
Other languages
English (en)
Chinese (zh)
Inventor
杰罗米·B·杰奥迪斯
帕特丽夏·E·W·罗汉
彼得·H·沙费尔·沙费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN101111235A publication Critical patent/CN101111235A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CNA2005800476591A 2004-12-13 2005-12-12 含有pde4调节剂的组合物以及它们在治疗或预防气道炎症中的用途 Pending CN101111235A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63498204P 2004-12-13 2004-12-13
US60/634,982 2004-12-13

Publications (1)

Publication Number Publication Date
CN101111235A true CN101111235A (zh) 2008-01-23

Family

ID=36121316

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800476591A Pending CN101111235A (zh) 2004-12-13 2005-12-12 含有pde4调节剂的组合物以及它们在治疗或预防气道炎症中的用途

Country Status (13)

Country Link
US (1) US20060148882A1 (enExample)
EP (1) EP1838294A1 (enExample)
JP (1) JP2008523102A (enExample)
KR (1) KR20070092276A (enExample)
CN (1) CN101111235A (enExample)
AR (1) AR052047A1 (enExample)
AU (1) AU2005316593A1 (enExample)
BR (1) BRPI0519030A2 (enExample)
CA (1) CA2590903A1 (enExample)
IL (1) IL183858A0 (enExample)
MX (1) MX2007006992A (enExample)
WO (1) WO2006065814A1 (enExample)
ZA (1) ZA200705540B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402980A (zh) * 2011-01-10 2013-11-20 细胞基因公司 作为pde 4 和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20070007945A (ko) * 2004-04-23 2007-01-16 셀진 코포레이션 폐 고혈압증의 치료 및 관리를 위한 ｐｄｅ4 조절인자의사용 방법 및 그를 포함하는 조성물
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
KR20110116049A (ko) * 2009-02-10 2011-10-24 셀진 코포레이션 결핵의 치료, 예방 및 관리를 위한 ｐｄｅ4 조절제를 포함하는 조성물 및 사용 방법
MX2011012122A (es) 2009-05-14 2012-02-28 Tianjin Hemay Bio Tech Co Ltd Derivados de tiofeno.
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
US20140018404A1 (en) 2010-12-16 2014-01-16 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2012096859A2 (en) * 2011-01-10 2012-07-19 Celgene Corporation Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
EP2683376B1 (en) 2011-03-07 2018-11-28 Celgene Corporation Methods for treating diseases using isoindoline compounds
KR101889757B1 (ko) 2011-04-28 2018-08-20 셀진 코포레이션 자가 면역 및 염증 질환의 치료 및 관리를 위한 ｐｄｅ4 저해제를 이용한 방법 및 조성물
WO2014151180A1 (en) 2013-03-14 2014-09-25 Celgene Corporation Treatment of psoriatic arthritis using apremilast
EP3096749B1 (en) * 2014-01-24 2019-05-15 Celgene Corporation Methods for the treatment of obesity using apremilast
EP3188745A1 (en) 2014-08-15 2017-07-12 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
US10011611B2 (en) 2015-08-14 2018-07-03 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
CA3034785C (en) * 2016-08-22 2022-11-15 Shijiazhuang Sagacity New Drug Development Co., Ltd. Pde4 inhibitor
DK3590924T3 (da) * 2017-02-28 2022-01-03 Kangpu Biopharmaceuticals Inc Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf
WO2018167142A1 (en) * 2017-03-16 2018-09-20 Takeda Gmbh Treatment of idiopathic pulmonary fibrosis
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7354948B2 (en) * 2002-11-06 2008-04-08 Celgene Corporation Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
AU2003294311B8 (en) * 2002-11-18 2008-06-05 Celgene Corporation Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CA2511843C (en) * 2002-12-30 2012-04-24 Celgene Corporation Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
KR20070007945A (ko) * 2004-04-23 2007-01-16 셀진 코포레이션 폐 고혈압증의 치료 및 관리를 위한 ｐｄｅ4 조절인자의사용 방법 및 그를 포함하는 조성물
US20080267905A1 (en) * 2004-05-05 2008-10-30 Celgene Corporation Methods and Compositions Using Selective Cytokine Inhibitory Drugs for Treatment and Management of Cancers and Other Diseases
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402980A (zh) * 2011-01-10 2013-11-20 细胞基因公司 作为pde 4 和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
CN103402980B (zh) * 2011-01-10 2016-06-29 细胞基因公司 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物

Also Published As

Publication number Publication date
IL183858A0 (en) 2007-10-31
AR052047A1 (es) 2007-02-28
ZA200705540B (en) 2009-01-28
AU2005316593A1 (en) 2006-06-22
US20060148882A1 (en) 2006-07-06
CA2590903A1 (en) 2006-06-22
JP2008523102A (ja) 2008-07-03
BRPI0519030A2 (pt) 2008-12-23
WO2006065814A1 (en) 2006-06-22
MX2007006992A (es) 2007-08-03
EP1838294A1 (en) 2007-10-03
KR20070092276A (ko) 2007-09-12

Similar Documents

Publication Publication Date Title
CN101111235A (zh) 含有pde4调节剂的组合物以及它们在治疗或预防气道炎症中的用途
US20050239867A1 (en) Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
KR20070010184A (ko) 폐 고혈압증의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 상기 화합물을 포함하는 조성물
EP1679967A2 (en) Methods of using and compositions comprising selective cytokine inhibitory drus for treatment, modification and management of pain
AU2010213936B2 (en) Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis
WO2005110085A2 (en) Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
US20070207121A1 (en) Methods of Using and Compositions Comprising Selective Cytokine Inhibitory Drugs for Treatment and Management of Macular Degeneration
HK1112197A (en) Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation
HK1103989A (en) Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
MXPA06004622A (en) Cytokine inhibitory drugs for treatment of macular degeneration
HK1103657A (en) Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
HK1103990A (en) Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes
KR20070011491A (ko) 골수이형성 증후군에서의 선택적 사이토킨 억제 약물의용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1112197

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080123

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1112197

Country of ref document: HK